Pete, I have nothing to hide. I am honest with my
Post# of 72445
Posted On: 11/29/2013 3:17:30 PM
Pete, I have nothing to hide. I am honest with my feelings and trades. CTIX is down 11% YTD and I do not see the share price reversing course significantly in the near term. I am going to put my money to work where I think it has the best chance for success. I have made a lot of money from CTIX. I follow it close enough that I am not going to miss something significant. This is my personal strategy, not advocating anyone do anything. If things change with CTIX, I have plenty of time to jump back in. My current issues (since you ask):
1. Accounting issues (reported on the recent S3) why should there be accounting issues when the company is run by a CPA?
2. "Going concern" label given to CTIX by auditors. If you read the S3 again, lots of bolded warnings and more warning than would seem typical.
3. More dilution with new Aspire deal for $20 million plus the "payoff" to Polymedix attorney. Potential for R/S heightened in the near term.
4. Sidetrack of Prurisol POC trial and potential "black box" label. Polymedix assets questionable.
5. Absolutely no institutional investors. No independent BOD. Uplisting won't happen anytime soon. Therefore, lack of appeal to more investors and institutions.
6. No significant update on p21 since April. No update on Kevetrin. Update probably not coming until Q2 2014.
7. Other better investment alternatives to put my money to work . . . just off the top of my head. Others should do there own DD. These are my opinions only. Again, Pete I will buy CTIX if/when things change, which could be at any moment.
1. Accounting issues (reported on the recent S3) why should there be accounting issues when the company is run by a CPA?
2. "Going concern" label given to CTIX by auditors. If you read the S3 again, lots of bolded warnings and more warning than would seem typical.
3. More dilution with new Aspire deal for $20 million plus the "payoff" to Polymedix attorney. Potential for R/S heightened in the near term.
4. Sidetrack of Prurisol POC trial and potential "black box" label. Polymedix assets questionable.
5. Absolutely no institutional investors. No independent BOD. Uplisting won't happen anytime soon. Therefore, lack of appeal to more investors and institutions.
6. No significant update on p21 since April. No update on Kevetrin. Update probably not coming until Q2 2014.
7. Other better investment alternatives to put my money to work . . . just off the top of my head. Others should do there own DD. These are my opinions only. Again, Pete I will buy CTIX if/when things change, which could be at any moment.
(0)
(0)